Examination of the Pancreas in New-onset Diabetes



Status:Active, not recruiting
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:50 - 85
Updated:3/21/2019
Start Date:May 2013
End Date:June 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Examination of the Pancreas in New-onset Diabetes (EXPAND Study)

The purpose of this study is to create a prospective cohort of subjects with increased
probability of being diagnosed with pancreatic cancer and then screen this cohort for
pancreatic cancer

Compared to the general population, subjects >50 years of age with new-onset diabetes (DM)
are 8-times more likely to have pancreatic cancer (PaC). The likelihood of PaC in new-onset
DM is further increased in those who have weight loss or elevated CA19-9. In this study
patients with newly diagnosed diabetes will be prospectively identified. Those with weight
loss and/or elevated pancreatic cancer marker (CA 19-9) will undergo pancreatic imaging. All
subjects will be followed up to 24 months. If successful in identifying surgically removable
PaC, this study will fundamentally change our practice and will be a major breakthrough in
PaC treatment and research.

Patient Characteristics:

--Suspected or definite new-onset diabetes based on recent blood sugar and hemoglobin A1c
values

- No acute illness or steroid therapy

- No prior pancreas surgery
We found this trial at
1
site
Mayo Clinic Rochester
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Suresh T. Chari, MD
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials